Peroxisome proliferators as adjuvants for the reverse-electron-transport therapy of obesity: an explanation for the large increase in metabolic rate of MEDICA 16-treated rats.
The efficacy of reverse-electron-transport therapy of obesity should be promoted by agents which up-regulate hepatocyte enzymes that are potentially rate-limiting for mitochondrial fatty acid oxidation and electron shuttles. Peroxisome proliferator drugs, including the fibrates used to treat hyperlipidemia, may be useful in this regard, as they induce malic enzyme, the mitochondrial glycerol-3-phosphate dehydrogenase, and carnitine palmitoyl transferase I in rodent hepatocytes. An agent of this class, MEDICA 16, has the additional property of potently inhibiting both citrate lyase and acetyl-CoA carboxylase. As a result, methyl-substituted diacarboxylic acids (MEDICA) 16 can be expected to disinhibit hepatic fatty acid oxidation while up-regulating electron shuttle mechanisms, and thus should stimulate reverse electron transport. This may explain the remarkable 40% increase in basal metabolic rate observed in normal rats ingesting MEDICA 16--an effect not associated with any compensatory increase in food intake. Relative to controls, the MEDICA 16-treated rats achieved a 50% reduction in body fat and a modest increase in lean mass, such that weight and growth were not changed. In other rodent strains, MEDICA 16 has prevented obesity diabetes and atherogenesis. However, whether MEDICA 16 and other peroxisome proliferator drugs will have clinical utility in reverse-electron-transport therapy may hinge on their ability to induce key enzymes in human hepatocytes; cell culture studies to evaluate this are required.
McCarty
M F
MF
Nutrition 21/AMBI, San Diego, CA 92109, USA.
D000103:Acetyl-CoA Carboxylase / Q000037:antagonists & inhibitors; D000818:Animals; D004579:Electron Transport; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors; D009765:Obesity / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D007652:Oxo-Acid-Lyases / Q000037:antagonists & inhibitors; D010169:Palmitic Acids / Q000494:pharmacology* / Q000627:therapeutic use; D020025:Peroxisome Proliferators / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats
D004791:Enzyme Inhibitors; D000960:Hypolipidemic Agents; D009097:Multienzyme Complexes; D010169:Palmitic Acids; D020025:Peroxisome Proliferators; C056166:MEDICA 16; D007652:Oxo-Acid-Lyases; C019909:citrate (pro-3S)-lyase; D000103:Acetyl-CoA Carboxylase